13G Filing: Sabby Capital and Northwest Biotherapeutics Inc (NWBO)
Sabby Healthcare Master Fund, Ltd | 0 | 15,761,350 | 0 | 15,761,350 | 15,761,350 | 4.99 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO CUSIP No. 6673P600 1.
Northwest Biotherapeutics Inc (NWBO)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Ancora Advisors Frederick Disanto | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 10,000 | Director | 10,000 | 2013-12-17 | Filing | |
| $4.80 | 43,602 | Director | 79,317 | 2012-10-10 | Filing | |
| $5.60 | 35,715 | Director | 35,715 | 2012-10-18 | Filing | |
| $5.60 | 3,013 | Director | 135,417 | 2014-08-01 | Filing | |
| $5.60 | 132,404 | Director | 132,404 | 2013-12-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.82 | 295,000 | Director | 0 | 2023-11-17 | Filing | |
| $0.82 | 150,000 | Director | 295,000 | 2023-11-17 | Filing | |
| $0.84 | 125,000 | Director | 445,000 | 2023-11-16 | Filing | |
| $0.17 | 3,558,639 | Large Shareholder, Officer, Director | 29,411,760 | 2018-12-27 | Filing | |
| $0.17 | 804,146 | Large Shareholder, Officer, Director | 0 | 2018-12-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 358,160 | $251,070 | 0.03% | |
| 2. | 44,000 | $30,844 | 0% | |
| 3. | 20,000 | $14,020 | 0% | |
| 4. | 4,292 | $3,145 | 0% | |
| 5. | 60,150 | $42 | 0% |
News See All
13G Filing: Woodford Investment Management and Northwest Biotherapeutics Inc (NWBO)
Please follow Woodford Investment Management (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Woodford Investment Management or update its stock holdings...
13G Filing: Sabby Capital and Northwest Biotherapeutics Inc (NWBO)
You can access the original SEC filing by clicking here.
Here's Why Traders Are Watching Coach, Red Robin, MGP Ingredients, and Two Other Stocks
Although the major indexes are relatively unchanged as the earnings results from Microsoft and other have failed to stir excitement in the broader market, traders are eagerly watching Coach Inc (NYSE...
Why Are These Steel And Biotech Stocks Deep In Red Today?
There is strong market activity in the last full trading day ahead of the Christmas weekend. U.S. stocks are in green territory, with the Dow up by triple digits, spurred by an increase in oil prices.
Woodford Investment Management Has A Lot Riding On These 5 Stocks
Woodford Investment Management recently filed its Form 13F with the U.S. Securities and Exchange Commission (SEC) for the reporting period of September 30.
Four Hot Biotechs Among The Day’s Big Winners
On a day when Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is deep in the red following the release of its third quarter earnings, four other biotech stocks are making strong gains.
Hedge Fund News: Louis Bacon, Paul Singer & Sandler Capital Management
Louis Bacon’s $15 billion (£9.3 billion) hedge fund Moore Capital boosted profits in its Mayfair office last year despite the loss of star fund manager Greg Coffey.
Hedge Funds Are Selling Affymax, Inc. (AFFY) - Northwest Biotherapeutics, Inc (NWBO), Celsion Corporation (CLSN)
In today’s marketplace, there are many metrics investors can use to watch Mr. Market. A couple of the most under-the-radar are hedge fund and insider trading interest.